OptiBiotix Health PLC (GB:OPTI)
LSE:OPTI
Top Page
OptiBiotix Health
(LSE:OPTI)
Select Model
Select Model
Rating:43Neutral
Price Target:
7.50 p
▲(11.11% Upside)
Action:N/ADate:01/04/26
The score is weighed down primarily by persistent losses and cash burn despite strong 2024 revenue growth, and by weak technicals showing a sustained downtrend with negative momentum. A debt-free balance sheet provides some support, but valuation remains difficult to justify with negative earnings and no dividend yield provided.
Positive Factors
Revenue growth acceleration
Sustained double-digit revenue acceleration indicates improving commercial traction and product adoption by partners. Over 2–6 months this supports scalability: higher revenues can spread fixed R&D and SG&A, improving the path to operating leverage if growth is sustained and order repeatability continues.
Negative Factors
Persistent negative cash flow
Consistent operating and free cash outflows imply the business is not yet self-funding. Over months this necessitates external funding or equity dilution, constrains marketing and commercial scale-up, and increases execution risk if new financing is delayed or terms are unfavourable.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth acceleration
Sustained double-digit revenue acceleration indicates improving commercial traction and product adoption by partners. Over 2–6 months this supports scalability: higher revenues can spread fixed R&D and SG&A, improving the path to operating leverage if growth is sustained and order repeatability continues.
Read all positive factors
OptiBiotix Health (OPTI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£5.06M
Dividend YieldN/A
Average Volume (3M)268.80K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding103,300,300
10 Day Avg. Volume266,472
30 Day Avg. Volume268,800
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)2.10
Price to Sales (P/S)20.26
P/FCF Ratio-9.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OptiBiotix Health Business Overview & Revenue Model
Company Description
OptiBiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food in...
How the Company Makes Money
OptiBiotix primarily makes money by monetising its health-ingredient technologies through B2B commercial agreements rather than selling directly to consumers. Key revenue streams include: (1) Ingredient sales: supplying its proprietary strains/ing...
OptiBiotix Health Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 870.00K | 644.00K | 457.00K | 2.21M | 1.52M |
| Gross Profit | 331.00K | 320.00K | 244.00K | 1.12M | 879.82K |
| EBITDA | -2.06M | -1.84M | 2.75M | 6.51M | 6.31M |
| Net Income | -1.80M | -2.04M | 2.59M | 6.26M | 5.80M |
Balance Sheet | |||||
| Total Assets | 9.04M | 9.40M | 11.55M | 20.14M | 13.70M |
| Cash, Cash Equivalents and Short-Term Investments | 739.00K | 635.00K | 1.05M | 2.01M | 864.68K |
| Total Debt | 0.00 | 0.00 | 0.00 | 819.36K | 771.76K |
| Total Liabilities | 647.00K | 532.00K | 643.00K | 1.97M | 1.85M |
| Stockholders Equity | 8.40M | 8.87M | 10.90M | 18.14M | 11.82M |
Cash Flow | |||||
| Free Cash Flow | -1.77M | -1.53M | -1.28M | -1.76M | -1.28M |
| Operating Cash Flow | -1.77M | -1.53M | -1.11M | -1.56M | -927.96K |
| Investing Cash Flow | 587.00K | 1.11M | -331.00K | -193.51K | -350.35K |
| Financing Cash Flow | 1.28M | 0.00 | 485.00K | 2.90M | 1.69M |
OptiBiotix Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | £6.57M | -0.92 | -115.97% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £4.19M | -0.88 | -53.79% | ― | ― | 85.56% | |
44 Neutral | £26.56M | -54.98 | -10.01% | ― | 283.74% | 78.57% | |
43 Neutral | £5.06M | -2.61 | -2.42% | ― | ― | ― | |
43 Neutral | £8.92M | -4,173.96 | -433.59% | ― | ― | ― | |
42 Neutral | £4.40M | -5.98 | -153.80% | ― | ― | -616.67% |
* Healthcare Sector Average
GB:OPTI
OptiBiotix Health
4.90
-10.35
-67.87%
GB:TCF
Evgen Pharma
0.20
-0.02
-11.36%
GB:FUM
Futura Medical
1.13
-9.37
-89.24%
GB:NFX
Nuformix Plc
0.17
0.06
55.56%
GB:CIZ
Cizzle Biotechnology Holdings PLC
2.25
0.70
45.16%
GB:SBTX
SkinBioTherapeutics
10.25
-14.25
-58.16%
OptiBiotix Health Corporate Events
Business Operations and StrategyProduct-Related Announcements
OptiBiotix Trials WellBiome to Boost Cardiac Surgery Outcomes and Cut NHS Costs
Positive
Feb 24, 2026
OptiBiotix Health has launched a double-blind, placebo-controlled clinical trial with Hull University Teaching Hospital NHS Trust to assess whether its patented prebiotic fibre complex WellBiome can improve cardiac surgery outcomes and reduce cost...
Business Operations and StrategyFinancial Disclosures
OptiBiotix Reassures Investors on Stakes in Affiliates as Cash and Sales Momentum Improve
Positive
Feb 17, 2026
OptiBiotix Health addressed investor concerns arising from recent announcements by SkinBioTherapeutics, stressing it has no current intention to sell its 5.64% stake in that company or its shares in ProBiotix Health. Management highlighted that th...
Business Operations and StrategyFinancial Disclosures
OptiBiotix Secures Record Early 2026 Orders as SlimBiome Demand Surges
Positive
Jan 21, 2026
OptiBiotix Health has secured four significant orders totalling 24 metric tonnes of its flagship weight management ingredient SlimBiome from Taiwanese distributor Meelung Trading, to be delivered in staged shipments throughout 2026, reflecting rap...
Business Operations and Strategy
OptiBiotix Launches Interactive Investor Hub to Deepen Shareholder Engagement
Positive
Jan 20, 2026
OptiBiotix Health has launched an interactive investor website that consolidates its corporate, commercial and research content into a single digital hub aimed at improving transparency and engagement with current and prospective shareholders. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.